Exclusivity Incentives In Cures Bill Not Overwhelmingly Costly, CBO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Small fraction of drugs likely would have generics delayed because of exclusivity for new rare disease indications.
You may also be interested in...
FDA Central Review Likely For Novel Surrogate Endpoints
CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.